Coronary Artery Disease
Coronary Artery Disease (CAD), also known as coronary heart disease (CHD) or ischemic heart disease (IHD), is a common cardiovascular condition caused by atherosclerosis, which leads to reduced blood flow to the heart muscle. Major risk factors include smoking, family history, high blood pressure, and high cholesterol, and it can manifest as stable angina, unstable angina, or myocardial infarction.
Health Outcomes
- Achieved Clinically Significant Systolic Blood Pressure Reduction
- Attenuated Blood Pressure (Inactivated Cells Only)
- Change in Waist-to-Hip Ratio
- Changed Leukocyte Telomere Length
- Changed Secretory Phospholipase A2 Level
- Controlled Serum Cholesterol Levels
- Decreased HDL Cholesterol Level
- Developed Polymorphic Ventricular Tachycardia
- Elevated Serum Lipoprotein Lipase Levels in Gilts
- Elevated Triglyceride Levels
- Endothelial Cell Damage
- Enhanced Aggregation Abilities
- Enhanced Antioxidant Levels
- Enhanced Cell Adherence
- Enhanced Co-aggregation Ability
- Enhanced Reverse Cholesterol Transport
- Extended Lifespan
- Identified ACE-Inhibitory Peptides
- Improved Aerobic Endurance Performance
- Improved Aerobic Power
- Improved Aerobic Stability
- Improved Ang-(1-7)/Ang II Ratio
- Improved Angina Symptom
- Improved Angiogenesis
- Improved Angiogenic Biomarker
- Improved Antithrombotic Prevention
- Improved ApoB-100/ApoA-1 Ratio
- Improved Arginine Metabolism
- Improved Arginine to Asymmetric Dimethylarginine Ratio
- Improved Atherogenic Index of Plasma
- Improved Atherosclerosis-Related Cardiovascular Risk Markers
- Improved Blood Biomarker Level
- Improved Blood Flow
- Improved Blood Lipid Profile
- Improved Brachial Artery Diameter
- Improved CVD-Related Symptom
- Improved Canadian Cardiovascular Society Angina Grade
- Improved Cardiac Baroreflex Sensitivity
- Improved Cardiac Histopathology
- Improved Cardiac Muscle Contractile Performance
- Improved Cardio-Metabolic Profile
- Improved Cardiometabolic Health
- Improved Cardiometabolic Score
- Improved Cardioprotective Activity
- Improved Cardiorespiratory Fitness
- Improved Cardiovascular Disease Marker
- Improved Cardiovascular Disease Outcomes
- Improved Cardiovascular Function
- Improved Cardiovascular Health
- Improved Cholesterol Levels
- Improved Cholesterol Metabolism
- Improved Cholesterol Profile
- Improved Cholesterol Regulation
- Improved Clinical Effective Rate
- Improved Clinical Efficacy
- Improved Clinical Success
- Improved Combined Cardiopulmonary Outcomes
- Improved Cycling Endurance
- Improved DASH Score
- Improved Diet
- Improved Diet Quality
- Improved Diet Quality Index
- Improved Disease Management
- Improved Early Postoperative Recovery
- Improved Endothelial Cell Migration
- Improved Endothelial Function
- Improved Endothelial Function Biomarker
- Improved Endothelial Health Marker Level
- Improved Endothelial Reactivity
- Improved Endothelium-Dependent Vasodilation
- Improved Endothelium-Dependent Vasodilation in Resistance Arteries
- Improved Endothelium-Independent Microvascular Vasodilation
- Improved Estimated VO2max
- Improved Event-Free Survival
- Improved Exercise Capacity
- Improved Exercise Duration
- Improved Exercise Endurance
- Improved Exercise Function
- Improved Exercise Performance
- Improved Exercise Stress Test Grade
- Improved Exercise Test Performance
- Improved Exercise Tolerance
- Improved Fibrinolytic Activity
- Improved Flow-Mediated Dilatation
- Improved Flow-Mediated Dilation
- Improved Flow-Mediated Vasodilation
- Improved Fractional Shortening
- Improved Functional Exercise Capacity
- Improved GDF-15 Level
- Improved Glutathione Peroxidase Level
- Improved Health Outcomes
- Improved Heart Rate Recovery
- Improved High-Density Lipoprotein Level
- Improved Hospital Discharge
- Improved Imaging Findings
- Improved LDL Cholesterol
- Improved LDL Subfraction Response
- Improved LDL-C to HDL-C Ratio
- Improved Left Ventricular Global Longitudinal Strain
- Improved Life's Essential 8 Score
- Improved Lipid Levels
- Improved Lipid Metabolism
- Improved Lipid Profile
- Improved Lipoprotein Subfraction Profile
- Improved Longevity
- Improved Low-Density Lipoprotein Composition
- Improved Maximal Exercise Capacity
- Improved Maximal Oxygen Consumption
- Improved Maximal Oxygen Uptake
- Improved Mean Arterial Pressure
- Improved Medication Adherence
- Improved Monocyte Activation
- Improved Myocardial Strain Rate
- Improved PRDX1 Gene Expression
- Improved Peak Oxygen Intake
- Improved Perceived Exertion
- Improved Physical Activity Initiation
- Improved Physical Activity Level
- Improved Physical Health
- Improved Physical Role Limitation
- Improved Plasma Cholesterol Clearance
- Improved Plasma Lipid Levels
- Improved Post-Myocardial Infarction Outcome
- Improved Prognosis of Type 2 Diabetes Mellitus
- Improved Pulse Wave Velocity
- Improved Reactive Hyperemia
- Improved Reactive Hyperemia Index
- Improved Running Performance
- Improved Serum Lipids
- Improved Stress-Strain Index
- Improved Survival at 24 Months
- Improved Tissue Inhibitor of Matrix Metalloproteinase-1 Level
- Improved Total Cholesterol Levels
- Improved Traditional Chinese Medicine Syndrome Effective Rate
- Improved Treatment Success
- Improved Troponin T Level
- Improved VO2max
- Improved Vascular Biomarker
- Improved Vascular Conductance
- Improved Vascular Endothelial Function
- Improved Vascular Function
- Improved Vascular Function in Offspring
- Improved Vascular Reactivity
- Improved Vascular Repair
- Improved Vasodilation
- Increased Apolipoprotein E Levels
- Increased Arginine/ADMA Ratio
- Increased Benefit Rate
- Increased Bioactivity
- Increased Blood Homocysteine Level
- Increased Body Mass Index
- Increased Bone Marrow Myelopoiesis
- Increased CD163+ Macrophage Density
- Increased CD34+ Cell Recruitment
- Increased CD68 to CD163 Ratio
- Increased CD68+ Macrophage Density
- Increased Circulating Vitamin K2 Levels
- Increased Endothelial Nitric Oxide Synthase Activity
- Increased Endothelial Progenitor Cell Count
- Increased Exercise Capacity
- Increased Flavanone Metabolite Excretion
- Increased Hemodynamic Disturbance
- Increased High-Density Lipoprotein Cholesterol
- Increased Homocysteine Level
- Increased Hospital Admissions
- Increased Inhibition of Lipid Oxidation
- Increased Invasive Interventions Requirement
- Increased L-Arginine to ADMA Ratio
- Increased L-arginine Level
- Increased LA/ADMA Ratio
- Increased LDL Cholesterol Level
- Increased Leptin Level
- Increased Lipid Oxidation
- Increased Low-Density Lipoprotein Cholesterol to Apolipoprotein B Ratio
- Increased Myeloperoxidase Activity
- Increased Myristic Acid Level
- Increased Nattokinase Activity
- Increased Nitric Oxide Bioavailability
- Increased Nitric Oxide Metabolite Levels in Metabolic Syndrome Patients
- Increased Nitric Oxide Synthase Activity
- Increased Osteopontin Level
- Increased Paraoxonase 1 Enzyme Activity
- Increased Peak Oxygen Uptake
- Increased Peak Systolic Velocity
- Increased Plasma Omega-3 Fatty Acids
- Increased Plasminogen Activator Inhibitor-1 Level
- Increased Risk of Cardiac Arrhythmias
- Increased SalA-like Inhibitory Activity
- Increased Serum High-Molecular Weight Adiponectin
- Increased Serum Nitric Oxide Level
- Increased Shear Force
- Increased Smoking Cessation Rate
- Increased Soluble Receptor of Advanced Glycation End Products
- Increased Soluble Vascular Cell Adhesion Molecule-1 Level
- Increased Triglyceride Level
- Increased VO2 Max
- Increased miRNA-503 Expression
- Increased n-3 Polyunsaturated Fatty Acid Levels
- Induced Health-Related Benefits
- Inhibited Lipid Oxidation
- Inhibited Platelet Aggregation
- Maintained High-Density Lipoprotein Levels
- Mitigated Cardiac Injury from Myocardial Infarction
- Modified LDL Phosphatidylcholine Composition
- Modulated Anterograde Blood Flow
- Modulated Anterograde Shear Rate
- Modulated Arterial Diameter
- Modulated Retrograde Shear Rate
- Multiple Health-Promoting Effects
- No Change in Major Cardiovascular Event
- No Improvement in Total Cholesterol
- No Reduction in Meat Cholesterol Levels
- No Significant Effect on Anxiety Levels
- Normalized Lipid Metabolism
- Normalized Lipid Profile
- Normalized Serum Lipid Levels
- Normalized Triglyceride
- Prevented Hypertension
- Prevented Vascular Calcification
- Prevention of Hypercholesterolemia
- Prolonged QT Interval
- Reduced 25-Hydroxycholesterol to Total Cholesterol Ratio
- Reduced 27-Hydroxycholesterol to Total Cholesterol Ratio
- Reduced 7-Hydroxycholesterol Level
- Reduced APO-B/A1 Ratio
- Reduced Adipokine Level
- Reduced Adiponectin Level
- Reduced Adverse Physiometabolic Effects
- Reduced Anger and Hostility
- Reduced Angina Pectoris Attack Frequency
- Reduced Angiopoietin-like Protein 3 Level
- Reduced Angiopoietin-like Protein 4 Level
- Reduced Aortic Stiffness
- Reduced Aortic Superoxide Levels
- Reduced Aortic Thickness
- Reduced Apelin Gene Expression
- Reduced Apo B to Apo A1 Ratio
- Reduced ApoB Level
- Reduced Apolipoprotein A-II Level
- Reduced Apolipoprotein A1 Level
- Reduced Apolipoprotein B Levels
- Reduced Apolipoprotein B to A-1 Ratio
- Reduced Apolipoprotein B-100
- Reduced Apolipoprotein B-100 to Apolipoprotein A-1 Ratio
- Reduced Apolipoprotein C-II Level
- Reduced Apolipoprotein C-III Level
- Reduced Arachidonic Acid to EPA Ratio
- Reduced Arterial Calcification Progression
- Reduced Arterial Calcification Score
- Reduced Arterial Calcifying Lesion Development
- Reduced Arterial Stiffness
- Reduced Asymmetric Dimethylarginine Level
- Reduced Atherogenic Index
- Reduced Atherosclerosis Risk Factors
- Reduced Atherosclerotic Cardiovascular Disease Event
- Reduced Atherosclerotic Plaque Formation
- Reduced Blood Cholesterol
- Reduced Blood Lipid Levels
- Reduced Blood Stream Cholesterol
- Reduced Cardiac Arrest Risk
- Reduced Cardiac Arrhythmia
- Reduced Cardiac Damage
- Reduced Cardiac Event
- Reduced Cardiac Function
- Reduced Cardiac Injury
- Reduced Cardiac Output
- Reduced Cardiovascular Disease Incidence
- Reduced Cardiovascular Disease Mortality
- Reduced Cardiovascular Disease Risk
- Reduced Cardiovascular Disease Symptom
- Reduced Cardiovascular Dysfunction
- Reduced Cardiovascular Event
- Reduced Cardiovascular Event Rate
- Reduced Cardiovascular Event Risk
- Reduced Cardiovascular Mortality
- Reduced Cause-Specific Mortality
- Reduced Central Blood Pressure
- Reduced Chest Pain
- Reduced Cholesterol Metabolism
- Reduced Community Healthcare Costs
- Reduced Contrast-Induced Acute Kidney Injury
- Reduced Coronary Artery Calcification
- Reduced Coronary Heart Disease Incidence
- Reduced Cumulative Incidents of CIDs in Smokers
- Reduced Cumulative Morbidity Rates
- Reduced Daytime Maximum Heart Rate
- Reduced Death Rate
- Reduced Dephosphorylated-Uncarboxylated Matrix Gla Protein Level
- Reduced Desphosphorylated-Uncarboxylated Matrix Gla Protein Level
- Reduced Dyslipidemia
- Reduced Dyslipidemia Parameters
- Reduced Exhaustion During Stress Test
- Reduced Flavonoid Levels
- Reduced Flow-Mediated Dilation
- Reduced Forearm Blood Flow Response to Acetylcholine
- Reduced Forward Wave Amplitude
- Reduced Forward Wave Pressure
- Reduced Glutathione Peroxidase Level
- Reduced HDL Cholesterol
- Reduced HDL Cholesterol Level
- Reduced HDL Levels
- Reduced HMG-CoA Reductase Inhibition
- Reduced Harmful Lipid Levels
- Reduced Heart Failure
- Reduced Heart Failure Risk
- Reduced Heart Rate Variability
- Reduced High-Density Lipoprotein (HDL) Cholesterol
- Reduced High-Density Lipoprotein Cholesterol Level
- Reduced High-Sensitive C-Reactive Protein Level
- Reduced High-Sensitivity C-Reactive Protein Level
- Reduced Hospitalisation
- Reduced Hospitalization
- Reduced Hospitalization Duration
- Reduced Hospitalization Requirement
- Reduced Hs-CRP Level
- Reduced Hydrogen Sulfide Level
- Reduced Hypercholesterolemia
- Reduced Hypercholesterolemia Incidence
- Reduced Hyperlipidemia
- Reduced Hyperlipidemia Symptoms
- Reduced Hypersensitive C-Reactive Protein Level
- Reduced Hypertension
- Reduced ICAM-1 Level
- Reduced In-hospital Mortality
- Reduced Incidence of Cardiovascular Disease
- Reduced Inflammatory Biomarker Level
- Reduced Intimal Thickening
- Reduced Ischemic Heart Disease Mortality
- Reduced LDL Aggregation
- Reduced LDL Cholesterol
- Reduced LDL Levels
- Reduced LDL Oxidation
- Reduced LDL to HDL Ratio
- Reduced LDL-C/HDL-C Ratio
- Reduced LDL-to-HDL Cholesterol Ratio
- Reduced LDL/HDL Ratio
- Reduced Large HDL Subfraction
- Reduced Left Ventricular Ejection Fraction Decline
- Reduced Lipid Peroxide Level
- Reduced Lipid Profiles
- Reduced Low-Density Lipoprotein Cholesterol
- Reduced Low-Density Lipoprotein Level
- Reduced Lymphocytic Genome Damage
- Reduced Lysophosphatidylcholine Level
- Reduced Matrix Gla Protein Level
- Reduced Matrix Metalloproteinase-1 Level
- Reduced Monocyte Adhesion
- Reduced Monocyte Chemoattractant Protein-1 Level
- Reduced Mortality Rate
- Reduced Myeloperoxidase (MPO) Concentration
- Reduced Myeloperoxidase Levels
- Reduced Myocardial Infarct Size
- Reduced Myocardial Injury
- Reduced Myocardial Injury Cytokines
- Reduced Nitric Oxide Level
- Reduced Nitric Oxide Production
- Reduced Non-Communicable Disease Risk
- Reduced Non-HDL Cholesterol
- Reduced Non-High-Density Lipoprotein Cholesterol
- Reduced Non-Infectious Complication Morbidity
- Reduced Obesity-Related Metabolic Disorder
- Reduced One-Year All-Cause Mortality
- Reduced Overall Complication
- Reduced Oxidative Stress
- Reduced Oxidative Stress Biomarker Level
- Reduced Oxidized LDL Level
- Reduced Oxidized Low-Density Lipoprotein Level
- Reduced Oxygen Consumption during Exercise
- Reduced Plaque
- Reduced Plasma Homocysteine Levels
- Reduced Platelet Aggregation
- Reduced Platelet Function Marker Level
- Reduced Platelet Hyperactivation
- Reduced Post-Exercise Serum Amyloid A Increase
- Reduced Postoperative Atrial Fibrillation
- Reduced Postoperative Complications
- Reduced Postoperative Pain
- Reduced Postoperative Pain Intensity
- Reduced Postprandial Triacylglycerol Response
- Reduced Postprandial Triglyceride Level
- Reduced Pro-oxidant-antioxidant Balance
- Reduced Protein Oxidation
- Reduced Redness at Surgical Site
- Reduced Sagittal Abdominal Diameter
- Reduced Serum C-reactive Protein Levels
- Reduced Serum Cholesterol Levels
- Reduced Serum LDL Levels
- Reduced Serum Lipid Levels
- Reduced Serum Plasminogen Activator Inhibitor-1
- Reduced Serum Total Cholesterol Levels
- Reduced Soluble CD14
- Reduced Soluble VCAM-1 Levels
- Reduced Statin Discontinuation Rate
- Reduced Surgical Site Bleeding
- Reduced Symptoms of High-Fat Diet Pathologies
- Reduced TMAO Production
- Reduced TXB2 Level
- Reduced Thrombosis
- Reduced Thromboxane A2 Level
- Reduced Tissue Inhibitor of Metalloproteinase 1 Level
- Reduced Total Cholesterol Levels
- Reduced Total Cholesterol to HDL Cholesterol Ratio
- Reduced Total Cholesterol:HDL Cholesterol Ratio
- Reduced Total Lipid Levels
- Reduced Triacylglycerol-Rich Lipoprotein Cholesterol Level
- Reduced Triglyceride Levels
- Reduced Triglyceridemia
- Reduced Trimethylamine N-oxide Level
- Reduced Trimethylamine N-oxide Levels
- Reduced Ultraprocessed Food Consumption
- Reduced Unstable Angina
- Reduced Urinary 8-Isoprostane Level
- Reduced Vascular Calcification
- Reduced Vascular Calcification Biomarker Level
- Reduced Vascular Calcification Progression
- Reduced Vascular Cell Adhesion Molecule-1 Level
- Reduced Vascular Damage
- Reduced Vascular Endothelial Growth Factor Level
- Reduced Vascular Restenosis
- Reduced Very Low-Density Lipoprotein
- Reduced Visfatin Level
- Reduced Vitamin K2 Status
- Reduced Yolk Cholesterol Content
- Reduced hsCRP Level
- Regulated Blood Lipid Levels
- Regulated Blood miRNA Expression
- Regulated Lipid Metabolism
- Regulated Lipid Metabolism in Epididymal Fat Pads
- Restored HDL Levels
- Restored Lipid Metabolism
- Safety Comparable to Control
- Stabilized Plasma Cholesterol Levels
- Stabilized Visceral Fat Area
- Stable High-Density Lipoprotein Cholesterol Level
- Stable Plasma Cholesterol Levels
- Unchanged Plasma Lipid Levels